Parkinson’s Disease Therapeutic Pipeline Analysis | Insights into the Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Amneal (IPX203), Pharma Two B (P2B001), Annovis Bio

September 20 20:38 2022
Parkinson's Disease Therapeutic Pipeline Analysis | Insights into the Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Amneal (IPX203),  Pharma Two B (P2B001), Annovis Bio
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 140+ key pharma and biotech companies are working on 150+ pipeline drugs in the Parkinson’s Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Parkinson’s Disease Market Size is anticipated to register immense growth in the coming years owing to a better understanding of the disease, emerging pipeline, and gene and stem therapies development.

Parkinson’s Disease Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Parkinson’s Disease Market. 

The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Parkinson's Disease Pipeline Analysis

Parkinson’s Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Parkinson’s Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Parkinson’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 150+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Recent Developments in the Parkinson’s Disease Therapeutics Market

  • August 31, 2022, Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced it had submitted a New Drug Application (NDA) to the US FDA for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD).

  • On August 24, 2022, Annovis Bio, Inc. announced that the first patient in Phase 3 clinical trial evaluating buntanetap in early Parkinson’s Disease (PD) has been dosed. The Phase 3 trial is a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap. The trial will enroll a total of 450 early PD patients.

The current emerging landscape for Parkinson’s Disease is vast, mainly comprising Phase II and Phase III candidate drugs. The therapies are expected to launch in the coming years.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Parkinson’s Disease Therapeutic Segment:

Parkinson’s Disease Therapeutics Landscape

There are approx. 140+ key companies which are developing therapies for Parkinson’s disease. Currently, Cerevel Therapeutics has its Parkinson’s disease drug candidates in the most advanced stage of clinical development. 

Key Companies in the Parkinson’s Disease Market include:

Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron,  Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc.. United Neuroscience Ltd., Luye Pharma Group,  AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd.,  Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd.,  NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx,  VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and Others.

Parkinson’s disease Emerging Drugs Covered in the report include:

  • Tavapadon: Cerevel Therapeutics

  • IkT-148009: Inhibikase Therapeutics

  • NLY01: Neuraly 

  • PT320: Peptron

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Parkinson’s Disease Current Treatment Patterns

4. Parkinson’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Parkinson’s Disease Late Stage Products (Phase-III)

7. Parkinson’s Disease Mid-Stage Products (Phase-II)

8. Parkinson’s Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Parkinson’s Disease Discontinued Products

13. Parkinson’s Disease Product Profiles

14. Key Companies in the Parkinson’s Disease Market

15. Key Products in the Parkinson’s Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Parkinson’s Disease Unmet Needs

18. Parkinson’s Disease Future Perspectives

19. Parkinson’s Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight 

Lower-Limb Spasticity Market

“Lower-Limb Spasticity Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Lower-Limb Spasticity  Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States